Valuation: Adocia

Market Cap 68.28M 77.82M 64.49M 58.77M 110M 7.46B 111M 772M 299M 3.81B 292M 286M 12.25B P/E 2026 *
8.69x
P/E 2027 * -31x
Enterprise Value 21.32M 24.3M 20.14M 18.35M 34.35M 2.33B 34.59M 241M 93.32M 1.19B 91.22M 89.25M 3.82B EV / Sales 2026 *
8.46x
EV / Sales 2027 * 3.83x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
1 week-4.05%
Current month-11.95%
1 month-13.35%
3 months-12.35%
6 months-27.71%
Current year-46.47%
1 week 2.59
Extreme 2.592
3.76
1 month 2.59
Extreme 2.592
4.15
3 years 2.59
Extreme 2.592
12.54
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 57 -
Director/Board Member 61 11/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-25.04%-4.05%-54.76%-55.73% 77.63M
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.31%-2.23%-13.47%+355.12% 26.54B
-0.35%+3.08%+0.96%-3.98% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
+0.70%-0.01%+50.83%+167.32% 14.36B
Average -0.44%-0.12%+27.44%+147.73% 30.46B
Weighted average by Cap. -0.75%-0.24%+37.12%+131.84%

Financials

2026 *2027 *
Net sales 2.52M 2.87M 2.38M 2.17M 4.06M 275M 4.09M 28.5M 11.04M 141M 10.79M 10.56M 452M 35.4M 40.34M 33.43M 30.47M 57.04M 3.87B 57.44M 400M 155M 1.98B 151M 148M 6.35B
Net income -423K -482K -399K -364K -681K -46.18M -686K -4.78M -1.85M -23.59M -1.81M -1.77M -75.82M -74.14M -84.49M -70.02M -63.81M -119M -8.1B -120M -838M -325M -4.14B -317M -310M -13.3B
Net Debt -46.97M -53.52M -44.36M -40.42M -75.67M -5.13B -76.21M -531M -206M -2.62B -201M -197M -8.42B 67.26M 76.65M 63.53M 57.89M 108M 7.35B 109M 760M 294M 3.75B 288M 282M 12.06B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
25/09/26 €2.628 -25.04%
24/09/26 €3.506 -0.40%
23/09/26 €3.520 -2.55%
22/09/26 €3.612 +0.39%
21/09/26 €3.598 -1.69%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.490EUR
Average target price
9.700EUR
Spread / Average Target
+177.94%

Quarterly revenue - Rate of surprise